Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood.

Slides:

Advertisements

Similar presentations

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic.

Advertisements

Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse.

Intensive Therapy before or during the Conditioning Regimen of Allogeneic Marrow Transplantation in Adult Acute Lymphoblastic Leukemia Patients: We Must.

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year.

Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Frans M. Verduyn Lunel,

Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

Biology of Blood and Marrow Transplantation

Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis Marie Robin, Federica Giannotti, Eric Deconinck, Mohamad Mohty,

Annalisa Ruggeri, Mary Eapen, Andromachi Scaravadou, Mitchell S

Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis Annalisa Ruggeri, Fernanda.

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study.

Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide,

Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity.

Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukemia Olga Nikolajeva,

Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report.

Effect of HLA-Matching Recipients to Donor Noninherited Maternal Antigens on Outcomes after Mismatched Umbilical Cord Blood Transplantation for Hematologic.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Sabina Kersting, Leo F. Verdonck

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis Marie Robin,

Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H

Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow.

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Paul Szabolcs, Donna Niedzwiecki

Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous.

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Efficacy and Outcome of Allogeneic Transplantation in IgD and Nonsecretory Myeloma. A Report on Behalf of the Myeloma Subcommittee of the Chronic Malignancies.

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise,

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.

Influence of Nucleated Cell Dose on Overall Survival of Unrelated Cord Blood Transplantation for Patients with Severe Acquired Aplastic Anemia: A Study.

Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the.

Kasiani C. Myers, Stella M. Davies

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.

Risk Factors for Late Infections after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Related Donor Marie Robin, Raphaël Porcher,

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Pauline Damien, David S. Allan

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

Gerard Socié, K. Scott Baker, Smita Bhatia

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation Stefan O. Ciurea, Victor Mulanovich,

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1 by Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri,

Blood and Marrow Transplant Handbook

Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy

Results of Unrelated Cord Blood Transplant in Fanconi Anemia Patients: Risk Factor Analysis for Engraftment and Survival Eliane Gluckman, Vanderson Rocha,

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion Laurent Garderet, Dimitris Ziagkos, Anja van Biezen, Simona.

Patrick J. Stiff, Manza-A. Agovi, Karen H

Mammen Chandy Biology of Blood and Marrow Transplantation

Eliane Gluckman Experimental Hematology

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Presentation transcript:

Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire Erick Xavier, Jérôme Cornillon, Annalisa Ruggeri, Patrice Chevallier, Jan J. Cornelissen, Niels S. Andersen, Natacha Maillard, Stephanie Nguyen, Didier Blaise, Eric Deconinck, Hendrik Veelken, Noel Milpied, Michel Van Gelder, Regis Peffault de Latour, Eliane Gluckman, Nicolaus Kröger, Johannes Schetelig, Vanderson Rocha Biology of Blood and Marrow Transplantation Volume 21, Issue 8, Pages 1515-1523 (August 2015) DOI: 10.1016/j.bbmt.2015.04.026 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) NRM according to fludarabine sensitivity (straight line represents fludarabine-refractory CLL/SLL and dotted line represents fludarabine-sensitive CLL/SLL). (B) NRM according to the number of previous lines of chemotherapy (straight line represents patients who received ≥3 lines of chemotherapy and dotted represents ≤2 lines of chemotherapy before UCBT). Biology of Blood and Marrow Transplantation 2015 21, 1515-1523DOI: (10.1016/j.bbmt.2015.04.026) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 PFS according to del 17p/p53mutations status. Biology of Blood and Marrow Transplantation 2015 21, 1515-1523DOI: (10.1016/j.bbmt.2015.04.026) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 (A) Overall PFS from the entire cohort of patients. (B) PFS according to fludarabine sensitivity. Biology of Blood and Marrow Transplantation 2015 21, 1515-1523DOI: (10.1016/j.bbmt.2015.04.026) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions